For Gen Sheng Wu, Ph.D., a member of the Molecular Therapeutics Research Program at the Barbara Ann Karmanos Cancer Institute and professor in the Department of Oncology and Pathology at Wayne State University School of Medicine, witnessing the research he began 20 years ago lead to a newly approved cancer treatment is a dream come true. ONC201, now renamed dordaviprone (ModeysoTM), was approved by the U.S. Food and Drug Administration (FDA) on August 6, 2025, to treat a rare and aggressive brain cancer...